Hong Kong stocks news | Pharmaron Health-B (02617.HK) rises by over 18% again, with a total market value exceeding HK$50 billion. The phase II trial of Tenofovir Alafenamide for breast cancer was approved.

According to the Securities Times APP, YJYAK- B (02617.HK) rose again by more than 18%, reaching a high of 129.3 Hong Kong dollars, setting a new record high, with a market value exceeding 50 billion Hong Kong dollars at one point. As of the time of writing, it has risen by 15%, trading at 125 Hong Kong dollars, with a turnover of 151 million Hong Kong dollars.